Altimmune, Inc.

As of February 28, 2023, Altimmune, Inc. is considered overvalued with a significant downgrade in investment appeal due to high financial metrics and negative returns compared to its peers, despite a recent stock return of 22.42%.

As of June 20, 2025, the market trend is neutral with mixed indicators, showing mild bullish momentum on weekly and monthly MACD, but short-term weakness in daily moving averages and indecision in RSI and OBV.

As of March 2022, the management team of Altimmune, Inc. includes Dr. Mitchel Sayare (Chairman), Dr. Vipin Garg (CEO), Dr. Diane Jorkasky, Dr. David Drutz, Mr. John Gill, Mr. Philip Hodges, and Mr. Wayne Pisano (all Independent Directors). They oversee the company's strategic direction and operations.

Altimmune, Inc. is a clinical-stage immunotherapeutics company focused on developing immune response products for disease prevention and treatment. As of March 2025, it has a market cap of $558.83 million, with net sales of $0 and a net loss of $20 million.

As of Jun 18, Altimmune, Inc. has a market capitalization of 558.83 million and reported net sales of 0.04 million with a net profit of -90.23 million over the latest four quarters. As of Dec 24, shareholder's funds were 123.51 million and total assets were 139.31 million.